What is the appropriate dosing of atomoxetine (Strattera) when taken concurrently with bupropion (Wellbutrin)?

Atomoxetine Dosing with Concurrent Bupropion

When taking atomoxetine (Strattera) concurrently with bupropion (Wellbutrin), you must reduce the atomoxetine dose to approximately 50% of the standard target dose due to a clinically significant drug-drug interaction that increases atomoxetine exposure by 5-fold.

Critical Drug Interaction

Bupropion is a potent CYP2D6 inhibitor, and atomoxetine is primarily metabolized through the CYP2D6 pathway 1. This creates a pharmacokinetic interaction that fundamentally alters atomoxetine metabolism:

• Atomoxetine exposure increases 5.1-fold when combined with bupropion 2
• Peak concentrations (Cmax) increase from 226 ng/mL to 386 ng/mL 2
• AUC increases dramatically from 1580 to 8060 ng*h/mL 2
• Half-life is prolonged 2

This interaction effectively converts a normal CYP2D6 extensive metabolizer into a poor metabolizer phenotype, where atomoxetine blood levels become 5-10 times higher than expected 1, 3.

Specific Dosing Algorithm

For patients on bupropion who need atomoxetine:

1. Initial dosing: Start atomoxetine at 0.5 mg/kg/day (or 40 mg/day for adults), which is half the standard starting dose 3

2. Titration: Increase slowly over a minimum of 4 weeks (not the standard 3 days) to allow assessment of tolerability 3

3. Target dose: Aim for approximately 0.7 mg/kg/day or 50-60 mg/day maximum (rather than the standard 1.2-1.4 mg/kg/day) 1, 3

4. Maximum dose: Do not exceed 80 mg/day total, which approximates the exposure seen in CYP2D6 poor metabolizers 3

For patients already on atomoxetine who start bupropion:

• Immediately reduce atomoxetine dose by 50% when initiating bupropion
• Monitor closely for 2-4 weeks as steady-state is reached
• Adjust based on efficacy and tolerability

Clinical Monitoring Priorities

Enhanced surveillance is mandatory because higher atomoxetine levels increase risks of:

• Cardiovascular effects: Monitor blood pressure and heart rate at each visit; atomoxetine shows signals for hypertension (ROR 2.9) and syncope (ROR 2.5) 4
• Gastrointestinal symptoms: Nausea, vomiting, abdominal pain are dose-dependent 1, 3
• Psychiatric effects: Increased irritability, aggression, or mood changes 3
• Urinary retention: Particularly in adults, where rates reach 1.7% even at standard doses 3

Important Caveats

This interaction is NOT theoretical - the 2016 clinical trial 2 demonstrated definitive pharmacokinetic changes in healthy volunteers. While the study authors noted that "additional studies are required to evaluate clinical relevance," the magnitude of the interaction (5-fold increase in exposure) makes dose reduction clinically prudent to avoid toxicity.

The FDA label for atomoxetine explicitly addresses CYP2D6 inhibition: It states that dosage adjustment is necessary when coadministered with potent CYP2D6 inhibitors like paroxetine, fluoxetine, and quinidine 3. While bupropion is not specifically listed, it functions as a potent CYP2D6 inhibitor through its metabolite hydroxybupropion.

Approximately 7% of Caucasian populations are naturally CYP2D6 poor metabolizers 1, 3, and these patients already require the lower dosing strategy outlined above. Bupropion essentially creates this phenotype pharmacologically in all patients.

Alternative Considerations

If the combination proves intolerable despite dose reduction:

• Methylphenidate does not share this interaction and may be preferable as first-line ADHD treatment 5, 1
• Guanfacine or clonidine are non-stimulant alternatives without CYP2D6 metabolism 1
• Sequential rather than concurrent therapy may be necessary if both medications are essential

The evidence strongly supports that atomoxetine and bupropion can be used together safely, but only with appropriate dose reduction of atomoxetine to account for the profound metabolic interaction 2.